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The emergence of drug-resistant parasites is a serious threat faced by malaria control programs. Understanding the genetic basis
of resistance is critical to the success of treatment and intervention strategies. A novel locus associated with antimalarial resis-
tance, ap2-mu (encoding the mu chain of the adaptor protein 2 [AP2] complex), was recently identified in studies on the rodent
malaria parasite Plasmodium chabaudi (pcap2-mu). Furthermore, analysis in Kenyan malaria patients of polymorphisms in the
Plasmodium falciparum ap2-mu homologue, pfap2-mu, found evidence that differences in the amino acid encoded by codon 160
are associated with enhanced parasite survival in vivo following combination treatments which included artemisinin deriva-
tives. Here, we characterize the role of pfap2-mu in mediating the in vitro antimalarial drug response of P. falciparum by gener-
ating transgenic parasites constitutively expressing codon 160 encoding either the wild-type Ser (Ser160) or the Asnmutant
(160Asn) form of pfap2-mu. Transgenic parasites carrying the pfap2-mu 160Asn allele were significantly less sensitive to dihy-
droartemisinin using a standard 48-h in vitro test, providing direct evidence of an altered parasite response to artemisinin. Our
data also provide evidence that pfap2-mu variants canmodulate parasite sensitivity to quinine. No evidence was found that
pfap2-mu variants contribute to the slow-clearance phenotype exhibited by P. falciparum in Cambodian patients treated with
artesunate monotherapy. These findings provide compelling evidence that pfap2-mu can modulate P. falciparum responses to
multiple drugs. We propose that this gene should be evaluated further as a potential molecular marker of antimalarial resistance.
Antimalarial drugs remain indispensable tools in the fightagainst malaria. The potent artemisinin derivatives, com-
bined with longer-half-life partner drugs, are the only efficacious
treatments left formultidrug-resistant Plasmodium falciparum in-
fection and thus form the cornerstone of antimalarial drug ther-
apy. The emergence of drug resistance represents one of the most
serious problems faced bymalaria control programs. Historically,
parasite resistance to antimalarial medicines emerged in South-
east Asia and eventually spread toward Africa, and, alarmingly,
there is already evidence of reduced susceptibility of P. falciparum
to artemisinin derivatives in Southeast Asia, as evidenced by de-
layed parasite clearance times in vivo (1–4). For now, the delayed-
clearance phenotype appears to be confined to the Greater Me-
kong subregion (5); however, this reduced artemisinin sensitivity
may spread to other regions or independently arise elsewhere,
includingAfrica, where the burden ofmalaria is highest andwhere
the emergence of resistance would have a terrible impact. A better
understanding of themechanisms of artemisinin resistance would
be amajor advance in our ability to develop and validate new tools
for resistance surveillance. These are essential tools to guide na-
tional treatment policies and help the design and deployment of
new drug combinations that may deter the emergence and spread
of resistance.
Mutations within the P. falciparum K13 kelch propeller do-
main gene (pfk13) recently identified in Cambodian parasite pop-
ulations have been proposed as amolecularmarker of artemisinin
resistance (6). Other genes acting together with pfk13 in Cambo-
dia may be involved in the slow-clearance phenotype in vivo, and
K13-independent mechanisms may have arisen in other settings.
Other potential genetic markers of artemisinin resistance have
previously been identified using genome-wide sequencing of
drug-pressured mutants of the rodent malaria parasite Plasmo-
dium chabaudi (7). One of these, the gene encoding the mu sub-
unit of the adaptor protein 2 (AP2) complex involved in clathrin-
mediated endocytosis, exhibits polymorphism in P. falciparum
isolates from Africa (8).
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We recently reported a phenomenon of submicroscopic per-
sistent parasites at day 3 following treatment with artemisinin
combination therapy (ACT) in Kenyan children. These persistent
parasites were detectable only by quantitative PCR (qPCR), but
the children carrying these parasites had a higher mosquito trans-
mission potential and were more likely to go on to classical treat-
ment failure at day 28 or 42 posttreatment (9). Sequence analysis
of these parasites revealed a particular genotype, combining vari-
ants of the pfcrt, pfmdr1, pfap2-mu, and pfubp1 candidate drug
resistance genes, which may modulate the responses to artemis-
inin combination treatments (10). This study specifically demon-
strated that a mutation in codon 160 encoding a change from Ser
(Ser160) to Asn/Thr (160Asn/Thr) in the P. falciparum ap2-mu
gene was a modulator of in vivo responses to artemisinin deriva-
tives in Kenyan malaria patients, being significantly more com-
mon among submicroscopic parasites surviving combination
treatment at day 3 than in the pretreatment population.
To explore the role of this putative artemisinin resistance
marker, we have generated transgenic P. falciparum parasites ex-
pressing an extra copy of either thewild-type (WT) pfap2-mu gene
or the 160Asn form, driven by a heterologous promoter, in addi-
tion to the endogenous WT pfap2-mu gene. The susceptibility of
these parasites to several antimalarial drugs (dihydroartemisinin
[DHA], quinine, chloroquine, lumefantrine, mefloquine, and
atovaquone)was compared to that of the parentalDd2attB strain in
a classical 48-h growth inhibition assay. DHA susceptibility of the
parasites was further evaluated using two alternative assays. The
first assay, established specifically for this study, deploys a 6-h
pulse of DHAwhile retaining an orthodox dose-response element
and does not require exhaustive parasite synchronization. This
assay was compared to the recently described ring-stage survival
assay (RSA), which exposes parasites at 0 to 3 h (RSA0–3h) postin-
vasion to a 6-h pulse of 700 nM dihydroartemisinin andmeasures
survival 66 h later (11).
MATERIALS AND METHODS
Culture of Plasmodium falciparum. The Dd2attB clone of P. falciparum
was generated by integration of the acceptor attB site, recognized by the
mycobacteriophage Bxb1 integrase during site-specific integration, into
the nonessential glutaredoxin-like cg6 gene located on chromosome 7.
Drug selection with 5 nMWR99210 was applied throughout to maintain
the presence of this site, as described previously (12). Parasite cultures
were maintained in complete growth medium composed of RPMI 1640
growthmedium supplementedwith 2.5% (vol/vol) humanAB serum, 147
M hypoxanthine, 5 g/liter Albumax II (Invitrogen), 10 mM D-glucose,
and 2 mM L-glutamine at 5% hematocrit in 5% CO2 at 37°C. Parasite
cultures were synchronized at the ring stage using sequential D-sorbitol
lysis treatment (13). Where not listed, reagents were obtained from
Sigma-Aldrich.
Generation ofP. falciparum transfection constructs.The open read-
ing frames of both the wild-type and mutant (160Asn) alleles of the
pfap2-mu gene (PlasmoDB identifier PF3D7_1218300) were amplified,
respectively, from genomic DNA of P. falciparum parasite line 3D7 and
from a P. falciparum field sample previously shown to harbor the 160Asn
mutation (10). The PCRprimers used are described inTable S1 in the sup-
plemental material. Plasmids pDC2-cam-pfap2-mu-attP and the pDC2-
cam-pfap2-mu160Asn-attP were then engineered (Fig. 1A). The pfap2-mu
amplicons were cloned as AvrII/XhoI fragments between the calmodulin
(PlasmoDB identifier PF3D7_1434200) promoter and the hsp86
(PlasmoDB identifier PF3D7_0708500) 3= untranslated region (UTR) in
the pDC2 vector (14), which also encodes a blasticidin-S deaminase (bsd)
selectable marker cassette. The resulting constructs were verified by se-
quence analysis, and DNA for transfection was purified using a Qiagen
CompactPrep Plasmid Maxi Kit.
For each duplex transfection, 50g of the plasmid containing the attP
site together with the pfap2-mu gene (WT or the 160Asn copy), 50 g of
the pINT plasmid containing the integrase expression unit that catalyzes
the recombination, and the neomycin resistance cassette (each in 25l of
Tris-EDTA [TE] buffer) were resuspended in 350l of CytoMix (120mM
KCl, 0.15 mM CaCl2, 2 mM EGTA [pH 7.6], 5 mM MgCl2, 10 mM
K2HPO4/KH2PO4 [pH 7.6], and 25 mM HEPES [pH 7.6]).
P. falciparum transfections. Transfections of P. falciparum were car-
ried out as described by Adjalley and colleagues (15), with slight modifi-
cations. Briefly, 250l of synchronized ring-stage Dd2attB-infected eryth-
rocytes at 6 to 9% parasitemia was added to 400 l of the duplex plasmid
preparation in electroporation cuvettes (Bio-Rad). Parasites were trans-
fected by electroporation (0.31 kV, 950F, and infinite resistance) (Gene
Pulser XCell; Bio-Rad) and then immediately transferred to culture flasks
containing 10 ml of complete medium and 250 l of newly harvested red
blood cells. Transfectants were allowed to recover in drug-free medium
for 24 h and then selected with 2.5g/ml blasticidin (Sigma-Aldrich) and
125g/ml of G418 (Invitrogen, Life Technologies). Drug pressure with
G418, selecting for the pINT plasmid, was applied for 6 days. The
mediumwas changed daily for the first 6 days, and then every other day
fresh medium containing the blasticidin and WR99210 selection
agents was added. Cultures were diluted 3:5 weekly (by the addition of
30% fresh blood cells) and monitored by Giemsa staining every 4 to 5
days for the appearance of the transfected parasites. Drug pressure was
maintained until the correct integration at the genomic attB locus was
verified by PCR. Two independent transfections for each pfap2-mu
plasmid were carried out.
Correct integration was verified by PCR using the P1/P2 primer pair
(Fig. 1; see also Table S1 in the supplemental material). The presence of
the pfap2-mu gene with the hsp86 3=UTR and the pfap2-mu gene was also
monitored using the P3/P4 and P5/P6 primer pairs, respectively (Fig. 1;
see also Table S1). Sequence analysis of themutation site G479A (160Asn)
was performed using the P5/P6 primer pair.
RNAextraction and cDNApreparation.For total RNA isolation, par-
asitized red cells were rapidly lysed in TRI reagent (Sigma-Aldrich) and
then stored at80°C prior to RNA extraction, according to themanufac-
turer’s protocol, as previously described (16). Briefly, the TRI reagent
lysates were thawed at 37°C, chloroform (Sigma-Aldrich) was added, and
the mixture was vigorously mixed and incubated for 15 min at room
temperature before centrifugation (12,000  g for 15 min at 4°C). The
aqueous phase was precipitated with isopropanol (Sigma-Aldrich), incu-
bated for 10min at room temperature, and centrifuged (12,000 g for 10
min at 4°C) to allow RNA precipitation, and the pellet was washed with
75% ethanol (Sigma-Aldrich). The samples were stored at 4°C overnight
and then centrifuged at 12,000  g for 10 min at 4°C. The ethanol was
removed, and the RNApellet was air dried before being resuspended in 20
l of nuclease-free water (Promega).
Extracted RNA was treated with RQ1 RNase-free DNase (Promega)
and reverse transcribed using gene-specific primers (Q2 and Q3) (see
Table S2 in the supplemental material) and a GoScript reverse transcrip-
tase kit (Promega), as described by the manufacturer. Each nuclease-
treated preparation was then split in two. In the control tubes, reverse
transcriptase was replaced with water (DNA contamination control).
Quantitative RT-PCR on ring-stage and late-stage samples of P. fal-
ciparummRNA.Quantitative reverse transcription-PCR (RT-qPCR)was
performed using a QuantiTect SYBR green PCR kit (Qiagen) in a Rotor-
Gene RG3000 machine (Corbett Research). Transcripts of the pfap2-mu
gene were amplified using the Q1/Q2 primer pair (see Table S2), and the
Plasmodium tRNA methionine (PgMET) gene was used as a reference
source of RNA. Previously published primer sequences Q3/Q4 (see Table
S2) were used to amplify the pgmet gene as described previously (17).
Reactions were carried out in 25-l volumes using QuantiTect SYBR
green PCR master mix according to the manufacturer’s guidelines. The
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PCR conditions consisted of 95°C for 6min, followed by 40 cycles of 95°C
for 15 s and 60°C for 1min for all reactions. Each parasite RNA samplewas
tested in triplicate in each experiment. Relative expression of pfap2-mu
was calculated from the average threshold cycle (CT) values from two
experiments normalized to pgmet using the CT method, where the
parental line was used as the comparator.
Standard 48-h drug susceptibility assays. Standard 48-h drug expo-
sure assays were performed to determine the susceptibility of parasites
to DHA, quinine, and chloroquine (representing 4-aminoquinolines),
lumefantrine and mefloquine (representing widely used ACT partner
drugs), and atovaquone (representing a well-characterized antimalar-
ial with a knownmode of action independent of the lysozome) accord-
ing to protocols for using the intercalating dye PicoGreen to provide a
fluorescent signal (18), as previously deployed in our laboratory (19).
The resulting 48-h 50% inhibitory concentration (IC50
48h) estimates
were used as primary indicators of antimalarial susceptibility, deter-
mined from a log dose-response analysis using Prism, version 6.04
(GraphPad Software, Inc., San Diego, CA). Each assay was performed
with two replicates on at least two (range, two to six) independent
occasions for each drug. For statistical analysis, best-fit estimates of the
IC50s and their 95% confidence intervals (CIs) were obtained by non-
linear regression fitting of the sigmoidal dose-response curve for each
drug across all experiments after normalization using control well
fluorescent signals. For statistical comparisons between the curve of
each transgenic strain and that of the parental strain and between the
curves of the two transgenic strains, data were first fitted indepen-
dently and then globally to find a shared best-fit value for the IC50
48h.
Results were compared by a sum-of-squares F test.
Artemisinin 6-h pulse assays. To generate IC50
6h estimates for arte-
misinin, we devised an alternative in vitro drug susceptibility protocol
designed to reduce the exposure of parasites to artemisinin in vitro so as to
more closely resemble the transient drug exposure of ACT-treated para-
FIG 1 Site-specific integration of the pfap2-mu gene (WT and 160Asn) into the P. falciparum Dd2attB line. (A) Schematic diagram of the integrase-mediated
attB attP recombination approach described by Nkrumah et al. (12). The top panel shows the cotransfected plasmids: plasmid pINT, carrying the integrase
expression unit that catalyzes the recombination and the neomycin resistance cassette (neo), and the pDC2-CAM-pfap2-mu-bsd-attP plasmid carrying theWT
or a mutant 160Asn pfap2-mu gene sequence under the control of the calmodulin promoter, a blasticidin resistance cassette (bsd) and the attP site. The middle
panel shows the recipient cg6-attB recombinant locus present in Dd2attB. The attB  attP recombination generates two sites, attL (left) and attR (right). The
human dihydrofolate reductase (hDHFR) represents the drug selection marker for WR99210. The lower panel represents the integration of the pDC2-CAM-
pfap2-mu-bsd-attP plasmid into the cg6-attB locus of Dd2attB. The position and orientation of the PCR primers (P1 to P6) used in the analysis of the transgenic
parasites are shown. (B) PCRmonitoring of integration of the pDC2-CAM-pfap2-mu-bsd-attP plasmid on the transfected parasites (two independent transfec-
tion experiments, A andB, for theWTand the 160Asnmutant). TheDd2attBDNAwas used as a control. The top panel shows integration of the blasticidin cassette
into the attB recombinant locus using the primers P1 and P2 (expected fragment size, 1,700 bp). The middle panel shows the presence of the pfap2-mu-hsp86 3=
UTR fusion (using the P3 and P4 primers; expected fragment size, 800 bp). The bottompanel shows the PCR product used to confirm the presence of the 160Asn
mutation by sequencing (using the P5 and P6 primers; expected fragment size, 840 bp).
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sites in vivo. DHA was serially diluted in complete medium (250 l) in
Eppendorf tubes, using the same 10 concentrations generated for the stan-
dard 48-h drug assays, so as to generate a full dose-response curve. A total
of 250 l of ring-stage culture, synchronized by a single round of 2%
D-sorbitol treatment (0 to 12 h postinvasion), was added to each drug
dilution (2% final hematocrit and 0.5% final parasitemia) and incubated
at 37°C for 6 h. After the incubation time, half of the culture was placed in
a 96-well tissue culture plate (modified 48-h assay), and the other half was
washed three times with 1,000 l of RPMI medium to remove DHA,
before being replenished with drug-free medium and placed in a 96-well
culture plate. The plate was then incubated at 37°C for 42 h until growth
assessment using the PicoGreen detection method, as described for the
standard 48-h assays, generating ameasure of DHA sensitivity in the form
of an IC50
6h estimate.
Ring-stage survival assay (RSA0–3h). The RSA0–3h was performed as
described by Witkowski and colleagues (11) with minor modifications.
The parasite cultures were tightly synchronized across two consecutive
ring-stage cycles with sorbitol treatment. Late-schizont-stage parasite cul-
tures were enriched using magnetic cell sorting (MACS) separation col-
umns (Miltenyi Biotech GmbH) and were cultured for 3 h at 37°C with
fresh erythrocytes and again sorbitol treated. This early-ring-stage (0 to 3
h) parasite preparation, at 1% parasitemia and 2% hematocrit in a 2-ml
final volume, was then exposed for 6 h to 700 nMDHA in 0.1% dimethyl
sulfoxide (DMSO). After the 6-h exposure the cultures were washed and
resuspended in drug-free culture medium and cultured at 37°C for a fur-
ther 66 h.Dihydroartemisinin susceptibility was then assessedmicroscop-
ically on thin films by estimating the percentage of viable parasites that
had developed into a new generation of trophozoites 66 h after DHA
exposure compared to results for parasites exposed to 0.1%DMSO alone.
This assay does not generate a dose-response curve.
RESULTS
Generation of transgenic parasites by integration of an addi-
tional copy of pfap2-mu in Dd2attB. To investigate the potential
role for the pfap2-mu 160Asn mutation in mediating reduced in
vitro susceptibility of P. falciparum to antimalarial drugs, we gen-
erated transgenic parasites with an additional copy of either the
wild-type Ser160 or the 160Asn mutant form of the pfap2-mu
gene. This was achieved using Bxb1mycobacteriophage integrase-
mediated recombination to deliver transgenes into the P. falcipa-
rum genome in a site-specific manner, dictated by the presence in
the parental line Dd2attB of the attB target sequence, replacing the
cg6 locus (12). The pfap2-mu gene, with or without the 160Asn
mutation, was cloned into the pDC2 plasmid under the control of
the calmodulin promoter (Fig. 1A) and cotransfected into the
Dd2attB strain with the pINT plasmid (encoding integrase) (12).
After transfection the parasites were placed under drug selection
with both blasticidin and G418, generating two transgenic lines,
termed Dd2attB::WT-pfap2-mu and Dd2attB::160Asn-pfap2-mu.
Stably transfected parasites were obtained 2 to 3 weeks after trans-
fection, and diagnostic PCRusing P1/P2 specific primers (Fig. 1 A;
see also Table S1 in the supplemental material) revealed correct
integration into the attB site. The presence of the pfap2-mu trans-
genes was confirmed by PCR analysis (Fig. 1 B; see also Table S1),
and the presence of the 160Asn mutation in the Dd2attB::160Asn-
pfap2-mu line was confirmed by sequencing.
RT-qPCRanalysis of pfap2-mu in transgenic lines.RT-qPCR
analysis of cultures of the parental and transfected parasite lines
provided evidence of constitutive blood-stage expression of the
introduced transgenes. In ring-stage cultures, 7.9-fold (160Asn-
pfap2-mu) and 23.8-fold (WT-pfap2-mu) overexpression of
pfap2-mu mRNA compared to the level in the parental line was
found in the transfectant lines, reflecting the known expression
profile of the calmodulin promoter (highly active across the 48-h
cycle with a distinct peak during the mid-trophozoite stage), but
late-stage cultures of both transfectant lines exhibited mRNA lev-
els similar to those of Dd2attB (Fig. 2). For each sample, parallel
reactions performed without reverse transcriptase did not gener-
ate detectable amplicons within 35 cycles, demonstrating the ab-
sence of detectable genomic DNA contaminating the RNA (data
not shown). Total RNA prepared from the peripheral blood of a
malaria patient as part of a previous study (19) was also analyzed
and confirmed transcription of pfap2-mu by circulating P. falcip-
arum blood-stage parasites in vivo.
In vitro sensitivity of pfap2-mu transfectant parasites. The
growth inhibition curves for DHA, quinine, chloroquine, and
lumefantrine for both transgenic lines are presented in Fig. 3. Ta-
ble 1 shows the mean ( standard deviation) IC50
48h estimates
calculated for the parental and transfected lines and the signifi-
cance of any differences in sensitivity between the different lines.
In four independent experiments, the transgenic parasite line har-
boring the 160Asn copy of the pfap2-mu gene displayed a signifi-
cantly reduced sensitivity to DHA (mean IC50
48h, 3.3 nM) com-
pared with the sensitivities of both the parent line (mean IC50
48h,
2.7 nM) and WT-pfap2-mu (mean IC50
48h, 2.5 nM) lines (Table
1). The quinine IC50
48h values increased significantly from 459.2
nM in the parental line and 471.5 nM in the WT-pfap2-mu to
671.2 nM in the 160Asn-pfap2-mu parasite line. The presence of
160Asn-pfap2-mu appeared to reduce susceptibility to chloro-
quine compared with that of the parental line. However, the WT-
transfected line exhibited an intermediate phenotype which was
not statistically different from the phenotypes of either the paren-
tal or mutant transgenic lines, and so no definite conclusions can
be made from the current data. Thus, decreased susceptibility to
DHA and quinine was conferred in these experiments by the pres-
ence of the 160Asn pfap2-mumutant allele, given that the overex-
pression of theWT allele had no effect on parasite susceptibility to
these antimalarials. In contrast, the Dd2attB::WT-pfap2-mu line
showed significantly reduced susceptibility to lumefantrine (IC50
of 57.7 nM) compared with that of the parental line (IC50 of 36.1
nM).However, as no significant difference was found between the
WT and the 160Asn lines or between the 160Asn and the parental
lines, the importance of this observation remains unclear. The pres-
FIG 2 Expression levels of pfap2-mu transcripts on ring-stage and late-stage
(trophozoites and schizonts) cultures of Dd2attB, Dd2attB::WT-pfap2-mu, and
Dd2attB::160Asn-pfap2-mu lines. Mean mRNA expression levels of pfap2-mu
in Dd2attB and transfected lines from RT-qPCR analysis are shown. The ex-
pression of pfap2-muwas normalized to themRNA level of PgMET. Error bars
indicate standard deviations.
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ence of 160Asn-pfap2-mu did not significantly alter parasite suscep-
tibility to atovaquone, a drug with a well-described mitochondrial
mode of action that is unrelated to that of the artemisinins or amino-
quinolines, nor did it alter mefloquine IC50s (Table 1).
The 6-h drug pulse assay, developed to better reflect the short
exposure times to artemisinin that occur in vivo, was used to esti-
mate the DHA IC50
6h for parental and transgenic lines. Figure 4
shows the best-fit curves generated, and IC50
6h estimates are indi-
cated in Table 2. The survival curves obtained in the 6-h pulse
assay showed a rightward shift toward higher DHA concentra-
FIG 3 Dose-response curves of the Dd2attB (parental), Dd2attB::WT-pfap2-mu, and Dd2attB::160Asn-pfap2-mu strains for dihydroartemisinin, quinine, chloro-
quine, and lumefantrine. The drug sensitivity of the parasites was assessed using a standard 48-h assay. Each point represents themean of at least two independent
experiments, with two replicates for each experiment. The error bars indicate standard errors of the means. Best-fit curves were generated by Prism, version
6.04. The x axis indicates the increasing concentrations of the different drugs, and the y axis indicates the parasite viability.
TABLE 1 In vitro drug susceptibility of the Dd2attB (parental), Dd2attB::WT-pfap2-mu, and Dd2attB::160Asn-pfap2-mu transfectant strains to six
antimalarial drugs
Drug (n)a
IC50 (nM) (95% CI)
b P valuec
Dd2attB (parental) Dd2attB::WT-pfap2-mu Dd2attB::160Asn-pfap2-mu WT vs Dd2attB 160Asn vs Dd2attB WT vs 160Asn
Dihydroartemisinin (4) 2.7 (2.6–2.9) 2.5 (2.0–3.1) 3.3 (2.9–3.8) 0.371 0.0057 0.0227
Quinine (3) 459.2 (413.3–510.3) 471.5 (442.1–502.9) 671.2 (582.3–773.6) 0.683 <0.0001 <0.0001
Chloroquine (4) 37.6 (25.9–54.5) 48.0 (29.6–78.0) 67.1 (58.6–76.8)d 0.445 0.0028 0.1429
Lumefantrine (2) 36.1 (28.3–46.2) 57.7 (43.0–77.4) 44.8 (32.3–62.1) 0.0294 0.3028 0.2517
Mefloquine (6) 13.1 (10.3–16.7) 16.7 (13.9–19.9) 17.0 (13.6–21.2) 0.1416 0.1488 0.8829
Atovaquone (4) 2.7 (2.3–3.4) 2.8 (2.3–3.5) 4.0 (2.7–6.0) 0.923 0.1014 0.1127
a n, number of independent experiments. Each experiment had two replicates.
b The drug sensitivity of the parasites was assessed using a classic 48-h growth inhibition assay. The best-fit curve for each drug was generated in Prism, version 6.04, and the best-fit
estimate of the IC50s and their 95% confidence intervals (CIs) are indicated.
c A sum-of-squares F test was used to test the significance of difference among the IC50s of the different parasites. The significant P values are indicated in bold.
d For Dd2attB::160Asn-pfap2-mu, only 3 experiments with chloroquine were performed.
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tions than the survival curves obtained in the modified 48-h assay
(i.e., with a 6-h tube incubation prior to plating) (see Materials
and Methods). These curve shifts meant that DHA IC50
6h esti-
mateswere always higher than the IC50
48h values by approximately
2-fold. Nevertheless, no significant difference was found between
the transfectant and the parental lines using either the IC50
48h or
IC50
6h estimate (Table 2). The IC50s obtained in themodified 48-h
assay were slightly higher (range, 3.9 to 4.1 nM) than the ones
obtained in the standard 48-h assay (range, 2.5 to 3.3 nM), possi-
bly due to differences in drug exposure arising from the initial 6-h
incubation in microcentrifuge tubes.
The susceptibility of young ring-stage (0 to 3 h) cultures to a
6-h pulse with 700 nM DHA was evaluated using the RSA0–3h of
Witkowski et al. (11). Parasite viability was zero, defined as more
than 99% of parasites recorded as dead at 72 h, in all test wells
(data not shown), indicating that parental and transgenic lines
were fully susceptible to DHA by this test.
DISCUSSION
In this study,we aimed to better understand the role of the ap2-mu
gene in influencing P. falciparum drug responses. pfap2-mu was
first implicated in artemisinin resistance in the rodent malaria
parasite P. chabaudi through whole-genome sequencing of a par-
asite lineage resistant to artemisinin, which identified a novel
Ile568Thr change as responsible for this phenotype by genome-
wide association analysis (8). Several variants of this gene were
identified in P. falciparum, but a polymorphism homologous to P.
chabaudi Ile568Thr has not been detected in field isolates to date
(8, 10). However, our recent work conducted in Kenya provides
evidence that a Ser160Asn/Thr mutation can modulate the para-
site response to artemisinin combination treatments in vivo (10).
Consistent with these results, we now show that transgenic para-
sites carrying 160Asn pfap2-mu are significantly less susceptible to
DHA in vitro, manifest as a 32% increase in the DHA IC50 com-
pared to the level in transgenic parasites carrying an additional
copy of the wild-type pfap2-mu locus, using a standard 48-h drug
susceptibility testing protocol (18, 19). Unexpectedly, transgenic
parasites carrying the 160Asn pfap2-mu allele were much less sus-
ceptible to quinine than were those with the wild-type allele, rais-
ing the intriguing possibility that quinine pressure in Kenya may
have been responsible for selecting the 160Asn allele in the parasite
population (10). In addition, this study provides weak evidence
that changes in the pfap2-mu sequence (for chloroquine) or ex-
pression level (for lumefantrine) also affect parasite sensitivity to
other antimalarials in vitro. Further experiments are needed to
confirm that the higher early-stage mRNA expression measured
here is accompanied by increased expression of the corresponding
protein but await the development of suitable reagents (i.e., spe-
cific antibodies). Additionally, it will be important to compare in
vitro susceptibility of the transgenic parasites to that of Cambo-
dian parasite lines with known clearance time phenotypes in both
the 48-h exposure dose-response assessment, generating IC50 es-
timates, and in the RSA0–3h assay.
The pfap2-mu gene is predicted to encode the mu () subunit
of the adaptor protein 2 (AP2) complex. AP2 facilitates formation
of clathrin-coated vesicles for the trafficking of cargo from one
membrane compartment of the cell to another by recruiting a
number of other proteins to the forming vesicle (20). AP2 is lo-
cated at the parasite plasmamembrane and also contributes to the
FIG 4 Dose-response curves of the Dd2attB (parental), Dd2attB::WT-pfap2-mu, and Dd2attB::160Asn-pfap2-mu transfectants for dihydroartemisinin. The drug
sensitivity of the parasites was assessed using a modified 48-h assay (solid line) and 6-h pulse assay (dashed line). Each point represents the mean of two
independent experiments, with two replicates for each experiment. The error bars indicate  standard errors of the means. Best-fit curves were generated by
Prism, version 6.04. The x axis indicates the increasing concentration of dihydroartemisinin, and the y axis indicates the parasite viability.
TABLE 2 In vitro drug susceptibility of the Dd2attB (parental), Dd2attB::
WT-pfap2-mu, and Dd2attB::160Asn-pfap2-mu transfectant strains to
dihydroartemisinin using a 6-h pulse assay
Strain
IC50 (nM) (95% CI)
a
Modified 48-h
assay 6-h pulse assay
Dd2attB (parental) 4.1 (3.7–4.6) 10.8 (8.6–13.5)
Dd2attB::WT-pfap2-mu 3.9 (3.8–4.1) 8.8 (8.1–9.4)
Dd2attB::160Asn-pfap2-mu 3.9 (3.6–4.2) 9.1 (6.3–13.1)
a The dihydroartemisinin susceptibility of each parasite line was assessed in both assays
by two independent experiments, with two replicates for each experiment.
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selection of specific cargo (21). The mu subunit binds to the cyto-
plasmic side of cargo molecules through recognition of specific
signals and is incorporated into themature clathrin-coated vesicle
(22), suggesting that AP2-mu variants may influence drug resis-
tance bymodulating cargo trafficking (8). The precisemechanism
by which polymorphisms in pfap2-mu affect antimalarial drug
response remains unknown. The P. chabaudi Ile568Thr mutation
is predicted to lie in the C terminus of the AP2-mu protein,
whereas the Ser160Asn mutation in P. falciparum is positioned in
the N-terminal domain. Both regions are highly conserved across
the genus, andby analogy to studies ofmammalian homologues, it
is predicted that both codons contribute to-sheet structure lying
within or adjacent to the hydrophobic pocket that binds to the
recognition motif present in the cargo protein (7). These muta-
tions may therefore mediate the antimalarial drug response by
reducing AP2-mu binding affinity to the membrane cargo and
thus decreasing the efficiency of endocytotic trafficking of mem-
brane proteins. A better understanding of AP2 variants requires
studies of the structure and function of the adaptor complex pro-
tein in Plasmodium spp.
The phenotype of reduced susceptibility to DHA described in
this study is moderate and unlikely to confer drug resistance in
itself; the phenomenon also appears to be significantly different
from the slow-clearance phenotype described in Southeast Asia,
which is associated with mutations in the pfk13 kelch propeller
domain (6, 23). First, the latter is associated with prolonged par-
asite clearance times in vivo and with increased survival in the
ring-stage parasite survival assay but not with any change in in
vitro susceptibility toDHAusing a standard 48-h drug assay.Here,
the transgenic population carrying the mutant pfap2-mu was
shown to be significantly less susceptible toDHA than the parental
population even though the IC50 was only marginally increased;
however, this “tolerant” phenotype was not detected using the
RSA0–3h and is thus distinct from the phenotype described by
Witkowski et al. (11). The three assays we deployed are not mea-
suring the same phenotypes as the duration of drug exposure dif-
fers markedly, and the RSA assay has no dose-response element.
Second, in contrast to the Southeast Asian isolates, the persistent
Kenyan parasites carrying the Ser160Asn/Thr mutation also carry
the chloroquine-sensitive haplotype pfcrt CVMNK and were mi-
croscopically undetectable; to date the pfk13 genotypes associated
with the Southeast Asian reduction in susceptibility have not been
seen in Kenyan parasites represented by the currently available
whole-genome sequence data (10).
The modulation of artemisinin sensitivity in an African con-
text clearly manifests as a different phenotype from the one de-
scribed in Cambodia, with different genes and genotypes impli-
cated; for example, no pfap2-mu codon 160 polymorphisms are
seen in publicly available genomes of any Southeast Asian isolates
(10). Conversely, African slow-clearing infections are not associ-
ated with polymorphisms in the kelch protein (4), suggesting the
contribution of other genetic factors. Furthermore, drug resis-
tance may not arise in a single step but as a long and complex
process during which parasites become gradually more and more
tolerant to the drug. This might result from the stepwise accumu-
lation of genetic changes in the same gene or in different genes
(24). Therefore, it is possible that mutations in AP2-mu are an
early step in one possible pathway for the development of artemis-
inin resistance and that additional genetic changes would be re-
quired before a fully resistant parasite genotype has emerged. This
is supported by our recent study in Kenya where variants at the
pfcrt, pfmdr1, and pfubp1 loci, as well as the pfap2-mumutations at
codon 160, were associated with posttreatment parasite persis-
tence (10). No genetic similarities to Cambodian P. falciparum
were seen at the four loci evaluated in this study, suggesting that
the two in vivo phenotypes are not related. Alternatively, AP2-mu
may contribute to a broad parasite heterogeneity that modulates
the drug response to several antimalarial drugs, as seen for pfmdr1
and othermembers of the ABC transporter family in P. falciparum
(25).
A potential restriction of our study is the sole use, as the parent
isolate, of Dd2attB, a transgenic line derived from the multidrug-
resistant Dd2 line that carries a chloroquine-resistant pfcrt allele
and amulticopy pfmdr1 locus conferring reducedmefloquine sus-
ceptibility but that remains sensitive to artemisinin. Dd2attB was
chosen for this purpose because in our hands it propagates more
rapidly than the few other lines available harboring the attB site
(14). The genetic background of the parasite can influence the
acquisition of drug resistance, so the drug responses observed in
this study may vary in isolates with a different preexisting drug
sensitivity background. For example, a significant increase in the
lumefantrine IC50
48h to 57.7 nMwas observed in theDd2attB::WT-
pfap2-mu transgenic parasites, which is well within the range we
have observed in patient isolates tested ex vivo (17). However, the
highest IC50
48h among these patient isolates occurred in those iso-
lates that were wild type for the chloroquine-associated resistance
marker pfcrt. In order to better understand the role of AP2-mu in
drug resistance, it is important to perform further genetic studies
in isolates with different backgrounds, including those with chlo-
roquine-sensitive genotypes and those with pfk13mutations, and
we are now pursuing such studies with recently developed gene-
editing approaches (26). Recent studies have now confirmed the
association between the artemisinin response in vitro and poly-
morphism in pfk13 by demonstrating an increase in survival in the
RSA0–3h assay in parasites engineered to express K13mutations, as
well as a loss of resistance in parasites whosemutant K13 gene was
reverted back to the wild-type sequence (23).
In summary, this study shows that expression of 160Asn
pfap2-mu in Dd2attB altered P. falciparum susceptibility to DHA,
with transgenic parasites exhibiting significantly higher IC50
48h
estimates. This confirms pfap2-mu as a locus of interest for studies
of artemisinin susceptibility. Our data also provide evidence that
pfap2-mu variants can modulate parasite susceptibility to quinine
in vitro.
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